With profitability reached last year, a rise in its stock price of more than 25 percent since the start of 2004, the FDA reviewing Thalomid for blood cancer and a 2-for-1 stock split due for shareholders next month, Celgene Corp. is sitting pretty - and also could be quite a takeover candidate for a deep-pocketed pharma company looking for a good cancer story. (BioWorld Financial Watch) Read More
